Voriconazole in the treatment of invasive mold infections in transplant recipients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 22, Issue 7, 2003, Pages 408-413

  Fortun J ^a   Martin Davila P ^a   Sanchez M A ^a   Pintado, V ^a   Alvarez, M E ^a   Sanchez Sousa A ^a   Moreno, S ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL INFECTION; ADULT; ARTICLE; ASPERGILLUS; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EYE INFECTION; FEMALE; HUMAN; LIVER TOXICITY; LUNG MYCOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SCEDOSPORIUM; VISUAL IMPAIRMENT;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FEMALE; FUNGI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; ORGAN TRANSPLANTATION; PYRIMIDINES; SCEDOSPORIUM; TRIAZOLES;

EID: 0041659184     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-003-0960-0     Document Type: Article

References (29)

1. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781-805
2. Paterson DL, Singh N (1999) Invasive aspergillosis in transplant recipients. Medicine 78:123-138
3. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M et al. (1995) Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 14:375-382
4. Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308-329
5. Verweij PE, Donnelly JP, Kullberg BJ, Meis JF, De Pauw BE (1994) Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22:81-85
6. Bowden R, Chandrasekar P, White M (1998) A double-blind randomised controlled trial of amphocil versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. In: Program and Abstracts of the International Immunocompromised Host Society Meeting, Davos, Switzerland, abstract no. 091. International Immunocompromised Host Society, Dacula, Georgia, USA
7. White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A et al. (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635-642
8. Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754-760
9. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383-1396
10. Oakley KL, Moore CB, Denning DW (1998) In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 42:91-94
11. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW (1998) In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 42:389-392
12. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A (1998) Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42:531-533
13. Murphy M, Bernard EM, Ishimaru T, Armstrong D (1997) Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41:696-698
14. Martin MV, Yates J, Hitchcock CA (1997) Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41:13-16
15. George D, Miniter P, Andriole VT (1996) Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40:86-91
16. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF (2000) Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44:2865-2868
17. Ascioglu S, Rex JH, Pauw B de, Bennett JE, Bille J, Crokaert F, Denning DW, the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
18. National Committee for Clinical Laboratory Standards (1998) Reference methods for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. NCLLS, Wayne, PA
19. Espinel-Ingroff A (2001) In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39:954-958
20. Espinel-Ingroff A, Bartlett V et al. (2001) Optimal susceptibility testing conditions for detection of resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 45:1828-1835
21. Denning DW (1996) Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23:608-615
22. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571
23. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
24. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234
25. Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E (2000) Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 31:1499-1501
26. Girmenia C, Luzi G, Monaco M, Martino P (1998) Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 36:1436-1438
27. Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B et al. (1998) Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 27:1437-1441
28. Poza G, Montoya J, Redondo C, Ruiz J, Vila N, Rodriguez-Tudela JL et al. (2000) Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 30:981-982
29. Wood N, Tan K, Allan R, Fielding A, Nichols DJ (2001) Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Abstract no. A-20